Verma Ravinder, Kumar Kuldeep, Bhatt Shailendra, Yadav Manish, Kumar Manish, Tagde Priti, Rajinikanth P S, Tiwari Abhishek, Tiwari Varsha, Nagpal Diksha, Mittal Vineet, Kaushik Deepak
Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani, Haryana, 127021, India.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India.
Recent Pat Nanotechnol. 2025;19(1):76-98. doi: 10.2174/1872210517666230731091046.
All over the world, cancer death and prevalence are increasing. Breast cancer (BC) is the major cause of cancer mortality (15%) which makes it the most common cancer in women. BC is defined as the furious progression and quick division of breast cells. Novel nanotechnology-based approaches helped in improving survival rate, metastatic BC is still facing obstacles to treat with an expected overall 23% survival rate. This paper represents epidemiology, classification (non-invasive, invasive and metastatic), risk factors (genetic and non-genetic) and treatment challenges of breast cancer in brief. This review paper focus on the importance of nanotechnology-based nanoformulations for treatment of BC. This review aims to deliver elementary insight and understanding of the novel nanoformulations in BC treatment and to explain to the readers for enduring designing novel nanomedicine. Later, we elaborate on several types of nanoformulations used in tumor therapeutics such as liposomes, dendrimers, polymeric nanomaterials and many others. Potential research opportunities for clinical application and current challenges related to nanoformulations utility for the treatment of BC are also highlighted in this review. The role of artificial intelligence is elaborated in detail. We also confer the existing challenges and perspectives of nanoformulations in effective tumor management, with emphasis on the various patented nanoformulations approved or progression of clinical trials retrieved from various search engines.
在全球范围内,癌症死亡率和患病率都在上升。乳腺癌(BC)是导致癌症死亡的主要原因(占15%),这使其成为女性中最常见的癌症。乳腺癌被定义为乳腺细胞的快速增殖和分裂。基于纳米技术的新方法有助于提高生存率,但转移性乳腺癌的治疗仍面临障碍,其总体生存率预计为23%。本文简要介绍了乳腺癌的流行病学、分类(非侵袭性、侵袭性和转移性)、风险因素(遗传和非遗传)以及治疗挑战。这篇综述文章重点关注基于纳米技术的纳米制剂在乳腺癌治疗中的重要性。本综述旨在提供对乳腺癌治疗中新型纳米制剂的基本见解和理解,并向读者解释如何持续设计新型纳米药物。随后,我们详细阐述了用于肿瘤治疗的几种纳米制剂类型,如脂质体、树枝状大分子、聚合物纳米材料等。本综述还强调了纳米制剂在乳腺癌治疗临床应用中的潜在研究机会以及与之相关的当前挑战。详细阐述了人工智能的作用。我们还讨论了纳米制剂在有效肿瘤管理方面现有的挑战和前景,重点介绍了从各种搜索引擎检索到的各种已获批准的专利纳米制剂或临床试验进展情况。